Search results for " biologic"

Article Maximum Output Starts with Optimized Upstream Processing
Significant growth in the development and manufacturing of biologics—from traditional recombinant proteins and monoclonal antibodies (mAbs) to advanced multispecifics, antibody-drug conjugates, viral …

Article Ensuring Viral Safety of Viral Vaccines and Vectors
However, because biological materials—cell substrates and often animal-derived products—are used in their manufacture, viral vaccines and vectors are at risk of contamination from micro-organisms, suc…

Article An Integrated Approach to Ensure the Viral Safety of Biotherapeutics
By Mark Plavsic Use of continuous cell lines in the manufacture of biological therapeutic products, such as vaccines, recombinant proteins, and monoclonal antibodies, is associated with the concom…

Article Prescribing Caution for Biosimilars
These legislative efforts represent a significant step in recognizing the important and complex role biologic medicines play in the future of healthcare and chronic disease management. They are also a…

Article Regulatory Challenges in the QbD Paradigm
This model is especially evident in FDA's Center for Drug Evaluation and Research (CDER) as used for therapeutic biological products, such as proteins and monoclonal antibodies. These products were tr…

Article Pharma Investments Reflect Key Industry Trends
First is the shift to biologic-based drugs, which has occurred along with a dramatic increase in the productivity, mainly in terms of much higher titers, of biopharmaceutical processes. “While demand …

Article Elucidating Biosimilars Characterization
The growth corresponds to a 20% increase from last year’s figures and accounts for approximately 2% of the overall biologics market. Although narrowly focused on only a small number of therapy areas a…

Article Reimagining Affordable Biosimilars
With an anticipated valuation of over $200 billion by 2022, this popularity of protein-based biologics can be attributed to their unique target specificity in protein–protein interactions for the trea…

Article Microbiological Testing: Time is of the Essence
Conventional protocols no longer suitable for traditional biologics Microbiology testing of pharmaceutical products is performed with a view to detection, enumeration, and identification of microbi…

Article Preclinical Evaluation of Product Related Impurities and Variants
Not all biologics can be subjected to a uniform panel of tests owing to their differences in their modes of action as well as their inherent biological/chemical complexities (8). In this 38th article …

Previous PageNext Page